Inventor · disambiguated record
Lie Li
Also filed as: LI LIE · LI LIE T · LI LIE TAO VICTOR
6 granted patents·20 pending applications·13 citations·filing 2006–2023
76Inventor score
Files withYICHANG HUMANWELL PHARMACEUTICAL CO LTD7WUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY6LIN HAIXIANG4HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC3Humanwell Pharmaceutical US2
Top patents by PatentIndex Score
26 records- 0186US8303966B2Immunogenic substances comprising a polyinosinic acid—polycytidilic acid based adjuvantLIN HAIXIANG·Filed 2011·Granted Nov 6, 2012·8 cites·19 claims
- 0275US11214577B2Morphinans useful for treating medical disordersHumanwell Pharmaceutical US·Filed 2020·Granted Jan 4, 2022·1 cites·12 claims
- 0372US9856262B2Analogues of 4H-pyrazolo[1,5-a] benzimidazole compound as PARP inhibitorsHUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC·Filed 2015·Granted Jan 2, 2018·2 cites·21 claims
- 0469US10428073B2Salt type and crystal type of 4H-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereofHUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC·Filed 2016·Granted Oct 1, 2019·1 cites·13 claims
- 0568US12221449B2Pyrrolopyrimidine derivative and use thereofWUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY·Filed 2020·Granted Feb 11, 2025·1 cites·13 claims
- 0666US10941150B2Salt type and crystal type of 4h-pyrazolo [1, 5-alpha] benzimidazole compound and preparation method and intermediate thereofHUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC·Filed 2019·Granted Mar 9, 2021·0 cites·12 claims
- 0760US2007166800A1Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvantLIN HAIXIANG·Filed 2006·Application pending·0 cites
- 0857US2022089605A1Novel morphinans useful for treating medical disordersHumanwell Pharmaceutical US·Filed 2021·Application pending·0 cites
- 0957US2009311334A1Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvantLIN HIAXIANG·Filed 2006·Application pending·0 cites
- 1056US2025248951A1Esketamine liquid preparation and use thereofYICHANG HUMANWELL PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1156US2025326755A1Cyclic quaternary ammonium salt compound, and preparation method therefor and use thereofYICHANG HUMANWELL PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1255US2024327383A1Piperidine derivative, and pharmaceutial composition thereof, preparation method therefor, and use thereofYICHANG HUMANWELL PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1354US2024342110A1Dexmedetomidine transdermal composition, transdermal patch and preparation method therefor and use thereofYICHANG HUMANWELL PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1454US2025221927A1Esketamine liquid preparation and use thereofYICHANG HUMANWELL PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1553US2009175902A1Immunogenic Substances Comprising A Polyinosinic Acid-Polycytidilic Acid Based AdjuvantLIN HAIXIANG·Filed 2006·Application pending·0 cites
- 1652US2025281426A1R-ketamine liquid preparation and use thereofYICHANG HUMANWELL PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1752US2024287021A1Quaternary ammonium salt compound, preparation method therefor and use thereofYICHANG HUMANWELL PHARMACEUTICAL CO LTD·Filed 2022·Application pending·0 cites
- 1852US2013115244A1Immunogenic Substances Comprising a Polyinosinic Acid - Polycytidilic Acid Based AdjuvantYISHENG BIOPHARMA SINGAPORE PTE LTD·Filed 2012·Application pending·0 cites
- 1951US2025214978A1At2r agonistWUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY·Filed 2023·Application pending·0 cites
- 2051US2023227445A1Benzamide compound and use thereofHUMANWELL HEALTHCARE GROUP CO LTD·Filed 2023·Application pending·0 cites
- 2148US2022056014A1Phenylpyrrolidine compound and use thereofWUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY·Filed 2019·Application pending·0 cites
- 2247US2023399314A1Cd73 inhibitor and use thereofWUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY·Filed 2021·Application pending·0 cites
- 2346US2022204479A1Pyrimidine compound and preparation method thereforWUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY·Filed 2022·Application pending·0 cites
- 2445US2007166239A1Mucosal immunogenic substances comprising a polyinosinic acid - polycytidilic acid based adjuvantLIN HAIXIANG·Filed 2006·Application pending·0 cites
- 2545US2023125494A1Synthesis of novel ep4 antagonist and use in cancer and inflammationWUHAN HUMANWELL INNOVATIVE DRUG RES AND DEVELOPMENT CENTER LIMITED COMPANY·Filed 2021·Application pending·0 cites
- 2633US2019054024A1Solid Dosage FormsHUMANWELL PHARMACEUTICAL US INC·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Lie Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →